In view of the repeated failures of new clinically Aβ targeted AD drugs, more attention switched to finding potential drugs targeting the hyperphosphorylation of tau protein to alleviate cognitive dysfunction in AD therapy. This evidence concerns the gene MAPT and Alzheimer disease.